Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
- 478 Downloads
Clinical trials suggest that increased risk of osteoporosis and fracture are the only serious side effects of adjuvant aromatase inhibitors (AIs), but little is known regarding toxicities of AIs in non-trial populations. We evaluated whether use of AIs was associated with myocardial infarction, stroke, and fracture in a community-based population. Using data from the HealthCore Integrated Research Database, 44,463 women aged ≥50 years with ≥2 breast cancer diagnosis codes between 2001 and 2007 were followed through 2008. Of these, 44,026 were matched using propensity score methods to women aged ≥50 years with no breast cancer codes. We assessed whether treatment with AIs was associated with myocardial infarction, stroke, and fracture using Cox proportional hazards models with time-varying treatment variables. Among breast cancer patients, 68.7% received no hormonal therapy, 20.6% received AIs (15.8% received only AIs, 4.8% were also treated with tamoxifen), and 10.7% received tamoxifen only. Breast cancer patients on AIs had a higher risk of any fracture (AHR = 1.13, 95% CI = 1.02–1.25) than breast cancer patients not receiving hormonal therapy. Patients on tamoxifen had a lower risk of hip fracture (AHR = 0.51, 95% CI = 0.32–0.81) than breast cancer patients not receiving hormonal therapy. Rates of myocardial infarction and stroke for patients on AIs or tamoxifen did not differ significantly from breast cancer patients not on therapy. The side effect profile of AIs in this community-based population was similar to that seen in clinical trials. These findings provide reassurance that AIs appear to be associated with few serious side effects.
KeywordsAromatase inhibitor Breast cancer Fracture Myocardial infarction Stroke Tamoxifen
This study was funded by the National Institutes of Health (R01 CA127652 to Dr. Keating).
Dr. Eric Winer received an honorarium from Novartis for consulting work. The other authors have no disclosures.
- 1.American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, AtlantaGoogle Scholar
- 2.Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRefGoogle Scholar
- 5.Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 369:559–570PubMedCrossRefGoogle Scholar
- 6.Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1–98 Study. J Clin Oncol 29:1117–1124PubMedCrossRefGoogle Scholar
- 8.Ries L, Eisner M, Kosary C (2003) SEER cancer statistics review, 1975–2000. National Cancer Institute, Bethesda, MDGoogle Scholar
- 9.Center for Disease Control and Prevention, Department of Vital Statistics. http://www.cdc.gov/nchs/nvss/mortality/lcwk10.htm
- 11.Thurlmann B, Keshaviah A, Mouridsen H, Mauriac L (2005) BIG 1–98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 23:511Google Scholar
- 13.Amir E, Ocana A, Niraula S, Carlsson L, Scruga B (2010) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients. In: San Antonio Breast Cancer symposium, Edition San Antonio, TXGoogle Scholar
- 14.Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, Milella M, Nistico C, Terzoli E, Cognetti F, Giannarelli D (2008) Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112:260–267PubMedCrossRefGoogle Scholar
- 16.Marciniak TA, Ellerbeck EF, Radford MJ, Kresowik TF, Gold JA, Krumholz HM, Kiefe CI, Allman RM, Vogel RA, Jencks SF (1998) Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 279:1351–1357PubMedCrossRefGoogle Scholar